JP2022540074A - イヌの慢性腎臓病の治療のためのテルミサルタン - Google Patents

イヌの慢性腎臓病の治療のためのテルミサルタン Download PDF

Info

Publication number
JP2022540074A
JP2022540074A JP2021578227A JP2021578227A JP2022540074A JP 2022540074 A JP2022540074 A JP 2022540074A JP 2021578227 A JP2021578227 A JP 2021578227A JP 2021578227 A JP2021578227 A JP 2021578227A JP 2022540074 A JP2022540074 A JP 2022540074A
Authority
JP
Japan
Prior art keywords
telmisartan
treatment
period
upc
levels
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021578227A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022540074A5 (enExample
Inventor
アン ミシェル トラース
コールマン アマンダ エリクソン
デ モウラ ロウレンソ ビアンカ ナタリア フェレイラ
ケイト エリザベス クリービー
スコット アラン ブラウン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Vetmedica GmbH
Original Assignee
Boehringer Ingelheim Vetmedica GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Vetmedica GmbH filed Critical Boehringer Ingelheim Vetmedica GmbH
Publication of JP2022540074A publication Critical patent/JP2022540074A/ja
Publication of JP2022540074A5 publication Critical patent/JP2022540074A5/ja
Priority to JP2025068236A priority Critical patent/JP2025120167A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2021578227A 2019-07-09 2020-04-30 イヌの慢性腎臓病の治療のためのテルミサルタン Pending JP2022540074A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025068236A JP2025120167A (ja) 2019-07-09 2025-04-17 イヌの慢性腎臓病の治療のためのテルミサルタン

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962871752P 2019-07-09 2019-07-09
US62/871,752 2019-07-09
PCT/US2020/030579 WO2021006941A1 (en) 2019-07-09 2020-04-30 Telmisartan for the treatment of chronic kidney disease in dogs

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025068236A Division JP2025120167A (ja) 2019-07-09 2025-04-17 イヌの慢性腎臓病の治療のためのテルミサルタン

Publications (2)

Publication Number Publication Date
JP2022540074A true JP2022540074A (ja) 2022-09-14
JP2022540074A5 JP2022540074A5 (enExample) 2023-05-11

Family

ID=70775531

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021578227A Pending JP2022540074A (ja) 2019-07-09 2020-04-30 イヌの慢性腎臓病の治療のためのテルミサルタン
JP2025068236A Pending JP2025120167A (ja) 2019-07-09 2025-04-17 イヌの慢性腎臓病の治療のためのテルミサルタン

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025068236A Pending JP2025120167A (ja) 2019-07-09 2025-04-17 イヌの慢性腎臓病の治療のためのテルミサルタン

Country Status (10)

Country Link
US (1) US20220218671A1 (enExample)
EP (1) EP3996705A1 (enExample)
JP (2) JP2022540074A (enExample)
KR (1) KR20220054291A (enExample)
CN (1) CN114450004A (enExample)
AU (1) AU2020311280B2 (enExample)
BR (1) BR112022000315A2 (enExample)
CA (1) CA3142876A1 (enExample)
MX (1) MX2022000429A (enExample)
WO (1) WO2021006941A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3996709A1 (en) 2019-07-09 2022-05-18 Boehringer Ingelheim Vetmedica GmbH Telmisartan for the treatment of hypertension in dogs

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ759782A (en) 2017-07-07 2023-06-30 Boehringer Ingelheim Vetmedica Gmbh Angiotensin ii receptor antagonist for the prevention or treatment of systemic diseases in cats

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
A．C. BUGBEE ET AL.: ""Telmisartan Treatment of Refractory Proteinuria in a Dog"", JOURNAL OF VETERINARY INTERNAL MEDICINE, vol. 28, no. 6, JPN6024014286, 30 September 2014 (2014-09-30), pages 1871 - 1874, XP055718581, ISSN: 0005692491, DOI: 10.1111/jvim.12471 *
酒井雄介他、蛋白漏出性腎症のイヌに対するテルミサルタンの抗蛋白尿効果の検討、日本獣医腎泌尿器学会誌、, JPN6024014285, pages 44 - 49, ISSN: 0005692490 *

Also Published As

Publication number Publication date
JP2025120167A (ja) 2025-08-15
BR112022000315A2 (pt) 2022-02-22
TW202116305A (zh) 2021-05-01
US20220218671A1 (en) 2022-07-14
AU2020311280B2 (en) 2026-05-07
KR20220054291A (ko) 2022-05-02
MX2022000429A (es) 2022-04-25
WO2021006941A1 (en) 2021-01-14
CN114450004A (zh) 2022-05-06
EP3996705A1 (en) 2022-05-18
AU2020311280A1 (en) 2022-02-24
CA3142876A1 (en) 2021-01-14

Similar Documents

Publication Publication Date Title
CA2496864C (en) A pharmaceutical composition
ES2972135T3 (es) Tratamiento de encefalopatía hepática usando rifaximina
CN102580095B (zh) 包含血管紧张素ii受体拮抗剂的药物组合物
EP3294283B1 (en) Sacubitril-valsartan dosage regimen for treating heart failure
KR102547164B1 (ko) 특정 환자 집단에서 신경퇴행성 장애를 치료하는 방법
EP4512397A2 (en) New use of a combination of an angiotensin receptor blocker (arb) with a neutral endopeptidase inhibitor (nepi)
JP2025120167A (ja) イヌの慢性腎臓病の治療のためのテルミサルタン
JP7402907B2 (ja) ネコの全身性疾患の予防又は治療用アンジオテンシンｉｉ受容体拮抗薬
JP2025115405A (ja) イヌの高血圧の治療のためのテルミサルタン
TW202541793A (zh) 用於預防貓之全身性疾病之血管緊張素ii受體拮抗劑
RU2832966C2 (ru) Телмисартан для лечения хронической болезни почек у собак
CN118078795A (zh) 乙酸异丁香酚酯在制备预防和/或治疗炎症性肠病的药物中的用途
RU2830555C2 (ru) Телмисартан для лечения гипертонии у собак
CN117396197A (zh) 慢性肾脏病的猫的治疗方法
US20260124187A1 (en) Compositions for the treatment of hypertension
JP2006117569A (ja) ステロイド依存性あるいはステロイド抵抗性潰瘍性大腸炎治療薬

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230428

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230428

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240415

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240716

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241015

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20241217

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250417